http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.jpg 144 Basel, 1 September 2010 - Straumann, a global leader in implant, restorative and regenerative dentistry today announced the initial market launch of its new CADCAM dental restoration system, which... http://pharmalicensing.com/redirs/news_rss//public/news/view/530911/6/0/straumann-launches-new-cadcam-dental-restoration-system http://pharmalicensing.com/redirs/news_rss//public/news/view/530911/6/0/straumann-launches-new-cadcam-dental-restoration-system Malvern, PA, [September 1, 2010] - Neuronetics, Inc., maker of the NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy http://pharmalicensing.com/redirs/news_rss//public/news/view/530872/6/0/neuronetics-selected-by-world-economic-forum-as-2011-technology-pioneer http://pharmalicensing.com/redirs/news_rss//public/news/view/530872/6/0/neuronetics-selected-by-world-economic-forum-as-2011-technology-pioneer SAN DIEGO, Aug 31, 2010 --Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States... http://pharmalicensing.com/redirs/news_rss//public/news/view/530901/6/0/quidel-announces-fda-clearance-of-its-rapidvue-r-hcg-pregnancy-lateral-flow-diagnostic-test http://pharmalicensing.com/redirs/news_rss//public/news/view/530901/6/0/quidel-announces-fda-clearance-of-its-rapidvue-r-hcg-pregnancy-lateral-flow-diagnostic-test IRVINE, Calif., Aug 31, 2010 -- Allergan, Inc. (NYSE:AGN) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% as a... http://pharmalicensing.com/redirs/news_rss//public/news/view/530849/6/0/allergan-inc-receives-fda-approval-for-lumigan-r-0-01-as-first-line-therapy-indicated-for-the-reduction-of-elevated-intraocular-pressure-in-glaucoma-patients http://pharmalicensing.com/redirs/news_rss//public/news/view/530849/6/0/allergan-inc-receives-fda-approval-for-lumigan-r-0-01-as-first-line-therapy-indicated-for-the-reduction-of-elevated-intraocular-pressure-in-glaucoma-patients LONDON, RESEARCH TRIANGLE PARK, N.C. and ALISO VIEJO, Calif., Aug 30, 2010--GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today the U.S. Food and Drug... http://pharmalicensing.com/redirs/news_rss//public/news/view/530755/6/0/gsk-and-valeant-announce-new-u-s-fda-pdufa-goal-date-for-ezogabine http://pharmalicensing.com/redirs/news_rss//public/news/view/530755/6/0/gsk-and-valeant-announce-new-u-s-fda-pdufa-goal-date-for-ezogabine August 30, 2010 - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received notification from the U.S. Food... http://pharmalicensing.com/redirs/news_rss//public/news/view/530701/6/0/eisai-announces-extension-of-fda-review-of-drug-application-for-investigational-agent-eribulin-mesylate http://pharmalicensing.com/redirs/news_rss//public/news/view/530701/6/0/eisai-announces-extension-of-fda-review-of-drug-application-for-investigational-agent-eribulin-mesylate Basel, 27 August 2010--Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's... http://pharmalicensing.com/redirs/news_rss//public/news/view/530673/6/0/roche-provides-update-on-fda-application-for-t-dm1 http://pharmalicensing.com/redirs/news_rss//public/news/view/530673/6/0/roche-provides-update-on-fda-application-for-t-dm1 South San Francisco, Calif. -- August 25, 2010 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) issued a Refuse... http://pharmalicensing.com/redirs/news_rss//public/news/view/530659/6/0/genentech-provides-update-on-fda-application-for-t-dm1 http://pharmalicensing.com/redirs/news_rss//public/news/view/530659/6/0/genentech-provides-update-on-fda-application-for-t-dm1 MISSISSAUGA, ON, Aug 10, 2010--JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis- YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced that the Office of Orphan Products... http://pharmalicensing.com/redirs/news_rss//public/news/view/530728/6/0/ym-biosciences-granted-orphan-drug-designation-for-cyt387 http://pharmalicensing.com/redirs/news_rss//public/news/view/530728/6/0/ym-biosciences-granted-orphan-drug-designation-for-cyt387 MISSISSAUGA, ON, Aug 05, 2010--YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo... http://pharmalicensing.com/redirs/news_rss//public/news/view/530727/6/0/ym-biosciences-announces-conclusion-of-phase-i-dose-escalation-and-expansion-of-ongoing-cyt387-phase-i-ii-clinical-study http://pharmalicensing.com/redirs/news_rss//public/news/view/530727/6/0/ym-biosciences-announces-conclusion-of-phase-i-dose-escalation-and-expansion-of-ongoing-cyt387-phase-i-ii-clinical-study